“CHPA advocates tirelessly to reinforce the value of OTC medicines, dietary supplements, and consumer medical devices and strengthen their relevance, importance, and credibility among key thought leaders and influencers.”
— Scott Melville, President & CEO, CHPA
On March 27, 2020, President Donald J. Trump signed into law H.R. 748, the “Coronavirus Aid, Relief, and Economic Security Act” or “CARES Act,” ushering in an exciting new chapter in OTC medicine history. The CARES Act included groundbreaking OTC Monograph reform legislation, which capped a multi-year effort to pass this landmark legislation, and will shape the future of OTC drugs for decades to come.
After a decade of lobbying, thanks to the unwavering effort of CHPA members and staff, 60+ million consumers can once again use their pre-tax HSA and FSA accounts to purchase OTC medicines without a prescription; and, for the first time ever, menstrual care products as well! When President Trump signed the CARES Act into law on March 27, 2020, it included the restoration of this key benefit and put wellness back in Americans’ wallets.